MedicineEurope PMC
Ranked by formulaVerdict: NotableOral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial
In hereditary angioedema, a rare bradykinin-mediated condition, oral on-demand treatments facilitating prompt administration and providing rapid, sustained relief and attack resolution remain scant.
Key numbers
- 2 × 2 crossover trial in
- 95% CI 1.05 to 1.52
- 3 days post-treatment
VerdictWorth a reader's time today.
Abstract
Background In hereditary angioedema, a rare bradykinin-mediated condition, oral on-demand treatments facilitating prompt administration and providing rapid, sustained relief and attack resolution remain scant. We investigated the efficacy and safety of deucrictibant, an oral bradykinin B2 receptor antagonist, for on-demand treatment of hereditary angioedema attacks. Methods RAPIDe-3 was a phase 3, double-blind, 2 × 2 crossover trial in adolescent and adult participants (aged ≥12 to 12), respectively (p<0·0001). Fatigue was the only adverse event reported more than once within 3 days post-treatment: a single event was reported by two participants, one of which was deemed unrelated to treatment. Across the study, no treatment-related adverse events were assessed as severe or serious, and no adverse events led to treatment discontinuation. Interpretation Oral deucrictibant provided faster times to symptom relief than placebo and was generally well tolerated. These results support the use of deucrictibant as potentially the first orally administered bradykinin B2 receptor antagonist for the treatment of attacks of bradykinin-mediated angioedema, including hereditary angioedema, and may address an unmet need for options that are effective and well tolerated, with convenient administration. Funding Pharvaris.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ███░░ 3 | 10% | A method or resource many groups across the field will adopt within a year. |
| Magnitude | ██░░░ 2 | 20% | Solid incremental gain on a meaningful problem. |
| Evidence | █████ 5 | 32% | Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale. |
| Novelty | ██░░░ 2 | 8% | A new combination of known ideas. |
| Trajectory | ███░░ 3 | 5% | A clear path to scale. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: breadth (many tasks); novelty (open problem); design (randomized, blinded, placebo-controlled); verification (confidence interval, p-value); scale (efficient); stakes (global scale, prevention or cure, genetic disease).
How the score was computed
- Merit
- 6.7 / 10
- Adjusted merit
- 5.4 / 10
- Attention
- 4%
- Freshness
- 53%
- Citations1 (reference 20, via openalex, Oct 17, 2026, 06:17 UTC)